Recommended stocks to buy today: Top stock choices by market experts for May 29

Copyright © HT Digital Streams Limit all rights reserved. Livemint 11 min Read May 29, 2025, 07:00 IT Recommended shares to buy today: Market experts recommend these shares for May 29. (Beeld: Pixabay) Summary Recommended Shares Today: Discover the best shares by market experts Raja Venkatraman, Marketsmith India, Ankush Bajaj and Trade Brains for Thursday 29 May. Indian benchmark indices expanded losses for a second consecutive session on Wednesday, May 28, weighed by declines in heavyweights such as ITC. This comes despite strong clues from Wall Street, as profit discussion in car, IT and metal supplies has added further pressure on the benchmarks. The Nifty 50 dropped 63 points, or 0.3%, at 24,752, while the Sensex dumped 240 points, or 0.29%, at 81,312. Sectoral weakness in FMCG, car, pharmaceutical and metal supplies further weighed on the index. In general, the market has remained careful before the most important emerging events, including the release of GDP growth data and the monthly F&O distribution. Here are the best stocks for today, as recommended by some of the leading market experts in India. Top 3 stock recommendations for today, May 29, by Ankush Bajaj Buy: Garden Reach Shipbuilders & Engineers Ltd (Current Price: £ 2,891) Why Grse is recommended: On the daily map, the stock showed a strong bullish momentum and broke out of a consolidation area, which indicates the potential for further upside. In addition, the stock at the lower timeframes gave an outbreak with volume, confirming the bullish setup and proposing a possible rally in the stock. IMPORTANT STATISTICS: RESISTANCE: £ 2,950-2,970 (short-term targets); Support level: £ 2,870 (pattern -valid level); Pattern: Bullish continuation of the continuation on the daily map; volume-backed outbreak at the lower timeframe; RSI: Bullish on both daily and lower timeframes, confirming the technical analysis of the exposition: The stock broke out of a bullish consolidation pattern, with a strong price action and succession. The RSI adds further confirmation to the bullish structure. Maintaining more than £ 2,891 increases the likelihood of reaching the target zone. Risk factors: A distribution below £ 2,870 can invalidate the exposition. Broader market weakness or negative sentiment can affect performance. Buy at: £ 2,891 Target Price: £ 2,950-2970 In 4-5 Days Stop Loss: £ 2.870 Buy: Mazagon Dock Shipbuilders Ltd (Current Price: £ 3.663) Why Mazagon Dock is recommended: At the lower timeframe, the stock formed a triangle pattern and a outbreak, which was a triangle pattern with a made potential formation. In addition, the share is trading near its lifetime high and it seems ready to make a fresh breakdown, suggesting a strong momentum and further upside down. IMPORTANT STATISTICS: RESISTANCE: £ 3,810-3,840 (short-term targets); Support level: £ 3,588 (pattern -valid level); Pattern: Triangle outbreak on the lower timeframe; near the lifetime high outline; RSI: Bullish on both daily and lower timeframes, confirming the technical analysis of the breakout: The stock showed strong bullish consolidation with an exposition of lower timeframes. It approaches a new lifetime high, supported by bullish RSI and a strong pricing structure. Maintaining more than £ 3,663 increases the likelihood that you can reach the target zone. Risk factors: Distribution among £ 3.588 can invalidate the exposition. Broader market weakness or negative sentiment can affect performance. Buy at: £ 3,663 Target Price: £ 3,810-3.840 in 4-5 Days Stop Loss: £ 3,588 Buy: Lt Foods Ltd (Current Price: £ 422) Why LT Foods is recommended: At the lower timeframes, the stock gave a rectangular outline, an indication of buildup and a fresh bullish. In addition, the stock broke out on the hourly chart from a rising wedge pattern, further confirming the bullish structure and the potential for an upward rally. IMPORTANT STATISTICS: RESISTANCE: £ 434-438 (short-term targets); Support level: £ 416 (pattern -valid level); Pattern: Rectangular outbreak on the lower timeframe; rising wedge outbreak on hourly map; RSI: Bullish on hourly and lower timeframes, confirming the technical analysis of the exposition: the combination of rectangle and rising wedge breakthroughs indicates a strong momentum and copper interest. The price action is supported by Bullish RSI, which gives the conviction of the exposition. Maintaining more than £ 422 increases the likelihood of reaching the target zone. Risk factors: Distribution under £ 416 can invalidate the exposition. Broader market weakness or negative sentiment can affect performance. Buy at: £ 422 Target Price: £ 434-438 in 4-5 Days Stop Loss: £ 416 Read More | The delays of project execution of NTPC remain its Achilles heel two shares recommendations for today, May 29, by Marketsmith India: Indraprastha Gas Ltd (Current Price: £ 213) Why It Is Recommended: Extension In New Markets, Government Support and Regulatory Kloofstatistics: P/E: 21.37 | 52-week High: £ 285.18 | PART: £ 113.69 Crore Technical Analysis: Recycle 200 EMA risk factors: Policy and regulatory risks, competition and market dynamics, technological disruptions buy at: £ 213 Target price: £ 245 in three months Stop loss: £ 199 Also read: Four shares to see as India’s space economy. Focused niche in secure MSME lending, low credit risk with a secure portfolio key statistics: P/E: 33.64 | 52-week High: £ 112.41 | PART: £ 88.24 Crore Technical Analysis: 21-DMA refusal Risk factors: Geographic concentration, interest rate sensitivity Buy at: £ 108.50 Target price: £ 122 in three months Stop loss: £ 103 shares to trade today as recommended by Trading Portal Portal: Balkrishna Industries Ltd. Months in 12 months stop: Why it is recommended: Balkrishna Industries is a leading player in the off -Highway Tire (OHT) market, which allows for sectors such as agriculture, construction, mining, forestry and industrial applications. With a global footprint in more than 160 countries and market customers, including John Deere, JCB, Caterpillar, Agco and Tafe, BKT is focused on an 8% share of the global OHT market. The company operates five tire manufacturing plants across Rajasthan, Maharashtra and Gujarat. In FY25, it sold 3,15,273 metric tons (MT) tires, growing 8% year-on-year. Financial Performance (FY25): Turnover: £ 10,447 Crore (+11.5% Yoy) Ebitda: £ 2.682 Crore (+16% Yoy) Ebitda margin: 25.26% (+50 BPS Yoy) Pat: £ 1.655 Crore (+12.5% ​​Yoy) of total FY25 volumes, 59.9% Off-the-road (OTR) segment. Europe accounted for 45.1% of volumes, while India contributed 28.6%. BKT led for 17% Cagr in turnover through FY30, with the aim of reaching £ 23,000 crore. It plans to invest £ 3.500 crore over the next three years to expand facilities in BHUJ for carbon black, power generation, CV tires, rubber tracks and PCR tires. In the OHT segment, continuous Capeex and De-Bottlenecking will increase the capacity by 35,000 MTPA to 425,000 MTPA. The company intends to increase the OHT segment’s contribution to 70% of the total revenue with FY30. Read more | Tata Sons feel the heat, as TCs are shrinking dividend for the first time in 20 years: BKT is significantly exposed to fluctuations in the prices of important raw materials such as natural rubber and crude oil derivatives. The company also has a risk to foreign exchange risks, as a large part of the revenue comes from India. Recent developments such as rates may affect BKT due to higher import costs. Symphony Ltd (Current Price: £ 1214) Target Price: £ 1.360 In 12 Months Stop loss: £ 1.140 Why it is recommended: Founded in 1988 in Gujarat, Symphony Ltd grew to a global air conditioning house with a presence in more than 60 countries. It is the world’s largest air conditioners manufacturer and recommends leadership in the segment with more than 25 million installations. The company has built up strong IP-led distinction, with 201 brands, 64 registered designs, 15 copyright and 48 patents. The product range contains 15+ industrial and commercial cooler models, supported by direct presence on four continents. Financial Performance (FY25): Income: £ 1.576 Crore (+36% Yoy) Ebitda: £ 316 Crore (+83% Yoy) Pat: £ 213 Crore (+44%) of total income, 90% (£ 1,065 crore) comes from the built -in market, with the remaining 10% (£ 117 crore). Symphony paste its global brand value to £ 13,000. The company focuses on expanding exports, especially to the US, Brazil, Europe, the Middle East and other regions with high potential. Brazil, the world’s fourth largest cooler market, remains a strategic focal point. Symphony plans to deepen its product offers and expand its dealer network. It is also investing in innovation features such as digital controls, fuzzy logic, stylized design and low-resource optimization. With the pioneers of BLDC (brushless DC car) in India, Symphony is now investigating the BLDC fans market. It aims to leverage the growing segment of $ 2 billion, which is expected to expand at 9-9.5% CAGR to 2029. Risk factors: Symphony has largely seasonal issues, so the demand estimates cannot work, as the company’s performance can fall if there is a weak or delayed summer. The company has an over-dependence on the air cooler segment, diversification of the product portfolio is needed as there is growing competition within the air cooling market. Two shares recommended by Raja Venkatraman of Neotrader Astra Microwave Ltd (current market price: £ 1163.70) Astra Microwave Products gave a good financial performance in Q4FY25, showing a strong growth in the air and defense sector. The last numbers reported indicated that revenue has now moved to £ 407.85 crore, reflecting an increase of 15.23%. Astra microwave maintained an operating margin of 26.60%, which despite the competition of the market, showing profitability. On a quarter-to-quarter basis, turnover increased by 57.75%, rising from £ 258.54 in the first quarter of the first quarter of £ 407.85 to £ 407.85 crore. Similarly, net revenue increased by 54.94% QOQ, strengthening financial strength. Another interesting news flow is that Radhakishan Damani, a well -known investor, returned to the company and participated in this fundraiser, further emphasizing the growing attraction of the market prospects of Astra Microgave. In addition to financial instruments, Astra Microwave has undergone leadership and board changes, which have introduced new strategic perspectives while adapting to developing operational dynamics. The share after a sterling performance until May 2024 had a major sale, much before the depletion of the market, and the profit discussion that followed has undergone a painful scenario in the last set of weeks, indicating that time is challenging. However, the strong decline has wiped out 50% of the increase seen since March 2023, to a strong range of supports around 600. At this level, prices had some steady buying interest that held the decline back, the prices pushed higher. The strong and steady increase we saw through live finances and strong participation helped the prices higher. In the end, the turnout succeeded in creating a new new highlight and the strong participation indicates a buying opportunity at the current and declines. Currently, the strong surge in prices has resulted in the prices doubling from the lows of March that emphasizes the strong recovery in this counter. The rapid turnaround in the trend of the share price of Astra microwave, which indicates strong investor confidence and optimism about future prospects. Looking at the future, Astra Microwave focuses on financial discipline, operational efficiency and S strategic investments will play an important role in shaping its future growth track and establishing himself as a leading player in the defensive industry. With increasing income, profitability of profitability Rings, investor confidence and corporate initiatives, Astra microwave is placed for sustained expansion. Considering the current scenario, one should consider buying at current levels and on dips near £ 1070 with a stop below £ 1045 for an increase up to £ 1280-1325. Glaxo Smithline Pharma (Current Market Price: £ 3348.20) GSK, is a global healthcare business specializing in pharmaceutical products, vaccines and healthcare products. It is one of the largest research -based pharmaceutical businesses in the world, focused on discovering, development, manufacturing and marketing human health products. GlaxoSmithline has a long history, with its origin in India dating back to 1924. In the last reported number Q4 FY25 GlaxoSmithline Pharmaceuticals Ltd. (GSK) showed strong financial performance, strengthening its position in the pharmaceutical sector. The company reported a 35% increase in the net profit, which reached £ 263 crore, compared to £ 194.48 in the same quarter last year. Operation revenue has risen to £ 974.37, which is reflected. GSK’s full -year turnover was £ 3.723 crore, which was a 9% increase, while profit after tax before exceptional items rose by 32% to £ 915. After a volatile upward trajectory since October 2023, the ride lower from July 2024 was a narrow one, as the rapid drop had no rest and was combined with the clumsy market forces that capitulated the trends. However, since the beginning of 2025, the situation has begun to improve, and prices have also taken into account the volatility around the Trump tariff performance. When things began to clear his position on Pharma and the implementation of the tariff, the resistance began to give away. As seen on the higher time frame maps, Glaxo showed long body pours that emphasize the robust participation. With the momentum that favored some potential upside down, the winds in this counter can carry the prices higher. The prices have witness to ominous volatility and the rapid recovery is definitely a signature of more upside down in the store. Looking forward, GSK remains committed to keeping a sustained growth above the market, focusing on innovation and strategic expansion. The company’s 100th Annual General Meeting is scheduled for June 27, 2025, where further strategic decisions are expected. With strong financial results, new product launches and a positive investor sentiment, GSK is well positioned for continued success in the pharmaceutical industry. With a robust volumes building up, you could consider buying dips near £ 3180, stop £ 3100 target £ 3480-3650. Also read: LIC’s growth-hazardous Curb Stock’s valuation Ankush Bajaj is a Sebi-registered research analyst. His registration number is INH000010441. Raja Venkatraman is co-founder, Neotrader. His SEBI registered research analyst registration no. is INH000016223. Marketsmith India: Brand Name: William O’Neil India Pvt. Ltd; SEBI-registered research analyst Registration Number: INH000015543 Trading Brains Portal is a stock analysis platform. The brand is Dailyraven Technologies Pvt. Ltd, and his SEBI registered registration number for research analysts are INH000015729. Investments in securities are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and Certification of Nisma does not guarantee the performance of the intermediary or ensuring returns to investors. Disclaimer: The views and recommendations given in this article are those of individual analysts. This does not represent the views of coin. We advise investors to check with certified experts before making investment decisions. Catch all the business news, market news, news reports and latest news updates on Live Mint. Download the Mint News app to get daily market updates. More Topics #nifty 50 #Sensex #Stock Recommendations #Markets Premium Read Next Story